← Return to Peripheral nerve stimulators

Discussion

Peripheral nerve stimulators

Neuropathy | Last Active: Oct 16, 2023 | Replies (259)

Comment receiving replies
@callalloo

If a company is publicly-traded, securities' analysts following it frequently are the canary in the coal mine about any problems with its key products. The institutional investors in Peloton were dumping the stock while it's sales were still growing despite the injuries and deaths of pets and toddlers under the stupidly-designed treadmills. And a subscription to the email notifications from the FDA about food, drug and med equipment recalls or investigations is a free resource. ('Free meaning you don't pay for it because it's funded with the taxes you already have to pay.)

For drugs, the FAERS public access to post-approval negative side effects ("adverse effects") is another canary in the coal mine. You can search by drug name and then sort the results in myriad ways including by adverse effects. (Amgen's Prolia has 117,000 reported side effects not listed in the company's package insert for consumers. 60,000 in one 2-year period. It's been on the market in the U.S. for just under eleven years. It's an injection given every 6 months. Meaning once in the body, it's, well, in the body until it's finally not.)

Jump to this post


Replies to "If a company is publicly-traded, securities' analysts following it frequently are the canary in the coal..."

Thank you for the information it helps that somebody cares